1800-272-662
Shopping Cart 0
countryflagAU
Login

Protagenic Therapeutics

Healthcare US PTIX

0.59USD
0.17(40.11%)

Last update at 2026-03-10T16:24:00Z

Day Range

0.510.59
LowHigh

52 Week Range

0.682.22
LowHigh

Fundamentals

  • Previous Close 0.42
  • Market Cap7.36M
  • Volume10533
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-5.48534M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-1.37

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -3.55551M -4.52293M -2.54874M -1.75091M -2.55753M
Minority interest - - - - 0.00000M
Net income -3.60156M -4.98664M -2.79491M -1.76680M -2.55753M
Selling general administrative 1.97M 3.00M 1.85M 1.28M 1.43M
Selling and marketing expenses - - - - -
Gross profit - - - - 0.00000M
Reconciled depreciation 0.00003M 0.00000M 0.00029M 0.00034M 0.00035M
Ebit -3.55779M -4.14041M -2.55161M -2.08613M -2.06793M
Ebitda -3.37197M -4.10721M -2.55082M -2.08298M -2.06759M
Depreciation and amortization 0.19M 0.03M 0.00079M 0.00315M 0.00035M
Non operating income net other - - - - 0.00000M
Operating income -3.55779M -4.14041M -2.55161M -2.08613M -2.31413M
Other operating expenses 3.56M 4.14M 2.55M 2.09M 2.31M
Interest expense 0.14M 0.50M 0.25M 0.02M 0.00279M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.19M 0.03M 0.00050M 0.00281M 0.00279M
Net interest income 0.05M -0.46370M -0.24568M -0.01307M 0.00279M
Extraordinary items - - - - 0.00000M
Non recurring - - - - 0.00000M
Other items - - - - 0.00000M
Income tax expense 0.05M 0.46M 0.25M 0.02M 0.49M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 3.56M 4.14M 2.55M 2.09M 2.31M
Cost of revenue - - - - 0.00000M
Total other income expense net 0.00228M -0.38252M 0.00288M 0.34M -0.24619M
Discontinued operations - - - - 0.00000M
Net income from continuing ops -3.55551M -4.52293M -2.54874M -1.75091M -2.55753M
Net income applicable to common shares - -4.52293M -2.54874M -1.75091M -2.55753M
Preferred stock and other adjustments - - - - 0.00000M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 4.32M 8.04M 11.06M 0.88M 0.84M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.14M 0.06M 0.69M 0.21M 0.04M
Total liab 0.66M 1.12M 1.12M 2.03M 1.48M
Total stockholder equity 3.67M 6.92M 9.94M -1.14974M -0.63437M
Deferred long term liab - - - - -
Other current liab 0.66M 0.11M 0.52M 0.51M 1.16M
Common stock 0.00044M 0.00043M 0.00172M 0.00104M 0.00103M
Capital stock 0.00044M 0.00043M 0.00172M 0.00104M 0.00103M
Retained earnings -30.77787M -25.77737M -22.22187M -17.69894M -15.15020M
Other liab - - - - -
Good will - - - - -
Other assets 0.00000M - - - -
Cash 1.29M 0.22M 0.54M 0.67M 0.80M
Cash and equivalents - - - - -
Total current liabilities 0.66M 1.12M 0.80M 0.66M 1.20M
Current deferred revenue - - - - -
Net debt -1.28789M 0.13M -0.22274M 0.70M -0.51925M
Short term debt - 0.34M 0.19M - -
Short long term debt - 0.34M - - -
Short long term debt total - 0.34M 0.32M 1.37M 0.28M
Other stockholder equity 34.56M 33.37M 32.41M 16.72M 14.69M
Property plant equipment - - - - 0.00030M
Total current assets 4.20M 8.04M 11.06M 0.88M 0.84M
Long term investments - - - - -
Net tangible assets - - 9.94M -1.14974M -0.63437M
Short term investments 2.77M 7.76M 9.83M - 0.25M
Net receivables - - - - -
Long term debt - - 0.32M 1.37M 0.28M
Inventory - - - - -
Accounts payable 0.00011M 0.67M 0.28M 0.14M 0.04M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.11355M -0.67691M -0.24835M -0.17159M -0.17236M
Additional paid in capital - - - - -
Common stock total equity - - - 0.00104M 0.00103M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other -0.00000M 0.00178M - - 0.00030M
Deferred long term asset charges - - - - -
Non current assets total 0.12M 0.00178M 0.00000M 0.00000M 0.00030M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 1.60M -9.90960M -9.90960M 0.25M 1.05M
Change to liabilities - 0.34M -0.19663M 0.66M 0.10M
Total cashflows from investing activities - -9.90960M -9.90960M 0.25M 1.05M
Net borrowings - - 1.33M 0.67M 0.67M
Total cash from financing activities 0.00000M 12.58M 1.22M 0.67M 0.67M
Change to operating activities - -0.48051M -0.16480M 0.04M 0.01M
Net income -3.55551M -4.52293M -2.54874M -1.75091M -2.55753M
Change in cash -0.32598M -0.12992M -0.12753M 0.44M -0.03720M
Begin period cash flow 0.54M 0.67M 0.80M 0.36M 0.40M
End period cash flow 0.22M 0.54M 0.67M 0.80M 0.36M
Total cash from operating activities -1.99381M -2.79861M -1.34878M -0.48799M -1.07119M
Issuance of capital stock 0.00000M 11.71M - - -
Depreciation 0.00003M 0.43M 0.00029M 0.00034M 0.00035M
Other cashflows from investing activities - - - - 0.00000M
Dividends paid - - - - 0.00000M
Change to inventory - - - - 0.00000M
Change to account receivables - - - - 0.00000M
Sale purchase of stock - - - - 0.00000M
Other cashflows from financing activities 1.60M 0.97M 1.22M 0.67M 1.05M
Change to netincome - 1.44M 1.41M 0.55M 1.38M
Capital expenditures 0.00180M 0.00000M 0.00000M 0.00000M 0.00000M
Change receivables - - - - 0.00000M
Cash flows other operating - - - - 0.00000M
Exchange rate changes - - - - 0.00000M
Cash and cash equivalents changes - - - - 0.00000M
Change in working capital 0.54M -0.14039M -0.36143M 0.70M 0.11M
Stock based compensation 0.86M 1.52M 1.65M 0.80M 1.13M
Other non cash items 0.16M 0.35M 0.15M 0.11M 0.25M
Free cash flow -1.99562M -2.79861M -1.34878M -0.48799M -1.07119M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
PTIX
Protagenic Therapeutics		 0.17 40.11% 0.59 - - - 1.74 -0.3153
NVO
Novo Nordisk A/S		 -1.06 2.66% 38.72 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 38.88 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 38.30 8.31% 499.17 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -9.57 1.22% 772.03 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.

Protagenic Therapeutics

149 Fifth Avenue, New York, NY, United States, 10010

Key Executives

Name Title Year Born
Dr. Garo H. Armen Ph.D. Co-Founder & Exec. Chairman 1953
Dr. Alexander Kenneth Arrow C.F.A., M.D. CFO & Sec. 1971
Dr. Andrew Slee Chief Operating Officer 1950
Dr. Robert Benjamin Stein M.D., Ph.D. Chief Medical Officer & Director 1951
Dr. David A. Lovejoy Chief Scientific Officer, Scientific Founder & Scientific Advisor NA
Dr. Garo H. Armen Ph.D. Co-Founder & Executive Chairman of the Board 1953
Dr. Alexander Kenneth Arrow C.F.A., M.D. CFO & Secretary 1971
Dr. Andrew Slee Ph.D. Chief Operating Officer 1950

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.